Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Article Title: Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignancies in vivo
doi: 10.1158/1078-0432.CCR-17-1193
Figure Lengend Snippet: (A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human NK-92-176V cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Article Snippet: Human NK-92 176V cells were obtained from Conkwest Inc. (San Diego, CA).
Techniques: Imaging, Luciferase, Expressing